> top > docs > PubMed:8724143 > annotations

PubMed:8724143 JSONTXT

Annnotations TAB JSON ListView MergeView

Glycan-Motif

Id Subject Object Predicate Lexical cue
T1 26-33 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T2 26-33 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T3 185-192 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T4 185-192 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T5 292-299 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T6 292-299 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T7 577-586 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin's
T8 577-586 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin's
T9 928-937 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin's
T10 928-937 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin's
T11 1020-1027 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T12 1020-1027 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T13 1062-1069 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T14 1062-1069 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T15 1466-1473 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T16 1466-1473 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T17 1521-1528 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T18 1521-1528 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T19 1667-1674 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T20 1667-1674 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T21 1694-1701 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T22 1694-1701 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin

GlyCosmos6-Glycan-Motif-Image

Id Subject Object Predicate Lexical cue image
T1 26-33 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T3 185-192 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T5 292-299 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T7 577-586 Glycan_Motif denotes heparin's https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T9 928-937 Glycan_Motif denotes heparin's https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T11 1020-1027 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T13 1062-1069 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T15 1466-1473 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T17 1521-1528 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T19 1667-1674 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO
T21 1694-1701 Glycan_Motif denotes heparin https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO

Glycosmos6-MAT

Id Subject Object Predicate Lexical cue
T1 1907-1911 http://purl.obolibrary.org/obo/MAT_0000135 denotes lung

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-161 Sentence denotes Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
TextSentencer_T2 162-399 Sentence denotes Structural features of heparin potentially important for heparanase-inhibitory activity were examined by measuring the ability of heparin derivatives to affect the degradation of [3H]acetylated heparan sulphate by tumor cell heparanases.
TextSentencer_T3 400-565 Sentence denotes IC50 values were determined using an assay which distinguished degraded from undegraded substrate by precipitation of the latter with cetylpyridinium chloride (CPC).
TextSentencer_T4 566-670 Sentence denotes Removal of heparin's 2-O-sulphate and 3-O-sulphate groups enhanced heparanase-inhibitory activity (50%).
TextSentencer_T5 671-793 Sentence denotes Removal of its carboxyl groups slightly lowered the activity (18%), while combining the treatments abolished the activity.
TextSentencer_T6 794-917 Sentence denotes At least one negative charge on the iduronic acid/idose moiety, therefore, is necessary for heparanase-inhibitory activity.
TextSentencer_T7 918-1004 Sentence denotes Replacing heparin's N-sulphate groups with N-acetyl groups reduced its activity (37%).
TextSentencer_T8 1005-1203 Sentence denotes Comparing this heparin derivative with 2,3-O-desulphated heparin, the placement of sulphate groups appears important for activity since the two structures have similar nominal linear charge density.
TextSentencer_T9 1204-1405 Sentence denotes In addition, unsubstituted uronic acids are nonessential for inhibition since their modification (periodate-oxidation/borohydride-reduction) enhanced rather than reduced heparanase-inhibitory activity.
TextSentencer_T10 1406-1675 Sentence denotes The most effective heparanase inhibitors (2,3-O-desulphated heparin, and [periodate-oxidized, borohydride-reduced] heparin) were tested in the chick chorioallantoic membrane (CAM) bioassay for anti-angiogenic activity and found to be at least as efficacious as heparin.
TextSentencer_T11 1676-1929 Sentence denotes 2,3-O-desulphated heparin also significantly decreased the tumor growth of a subcutaneous human pancreatic (Ca-Pan-2) adenocarcinoma in nude mice and prolonged the survival times of C57BL/6N mice in a B16-F10 melanoma experimental lung metastasis assay.
T1 0-161 Sentence denotes Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
T2 162-399 Sentence denotes Structural features of heparin potentially important for heparanase-inhibitory activity were examined by measuring the ability of heparin derivatives to affect the degradation of [3H]acetylated heparan sulphate by tumor cell heparanases.
T3 400-565 Sentence denotes IC50 values were determined using an assay which distinguished degraded from undegraded substrate by precipitation of the latter with cetylpyridinium chloride (CPC).
T4 566-670 Sentence denotes Removal of heparin's 2-O-sulphate and 3-O-sulphate groups enhanced heparanase-inhibitory activity (50%).
T5 671-793 Sentence denotes Removal of its carboxyl groups slightly lowered the activity (18%), while combining the treatments abolished the activity.
T6 794-917 Sentence denotes At least one negative charge on the iduronic acid/idose moiety, therefore, is necessary for heparanase-inhibitory activity.
T7 918-1004 Sentence denotes Replacing heparin's N-sulphate groups with N-acetyl groups reduced its activity (37%).
T8 1005-1203 Sentence denotes Comparing this heparin derivative with 2,3-O-desulphated heparin, the placement of sulphate groups appears important for activity since the two structures have similar nominal linear charge density.
T9 1204-1405 Sentence denotes In addition, unsubstituted uronic acids are nonessential for inhibition since their modification (periodate-oxidation/borohydride-reduction) enhanced rather than reduced heparanase-inhibitory activity.
T10 1406-1675 Sentence denotes The most effective heparanase inhibitors (2,3-O-desulphated heparin, and [periodate-oxidized, borohydride-reduced] heparin) were tested in the chick chorioallantoic membrane (CAM) bioassay for anti-angiogenic activity and found to be at least as efficacious as heparin.
T11 1676-1929 Sentence denotes 2,3-O-desulphated heparin also significantly decreased the tumor growth of a subcutaneous human pancreatic (Ca-Pan-2) adenocarcinoma in nude mice and prolonged the survival times of C57BL/6N mice in a B16-F10 melanoma experimental lung metastasis assay.
T1 0-161 Sentence denotes Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
T2 162-399 Sentence denotes Structural features of heparin potentially important for heparanase-inhibitory activity were examined by measuring the ability of heparin derivatives to affect the degradation of [3H]acetylated heparan sulphate by tumor cell heparanases.
T3 400-565 Sentence denotes IC50 values were determined using an assay which distinguished degraded from undegraded substrate by precipitation of the latter with cetylpyridinium chloride (CPC).
T4 566-670 Sentence denotes Removal of heparin's 2-O-sulphate and 3-O-sulphate groups enhanced heparanase-inhibitory activity (50%).
T5 671-793 Sentence denotes Removal of its carboxyl groups slightly lowered the activity (18%), while combining the treatments abolished the activity.
T6 794-917 Sentence denotes At least one negative charge on the iduronic acid/idose moiety, therefore, is necessary for heparanase-inhibitory activity.
T7 918-1004 Sentence denotes Replacing heparin's N-sulphate groups with N-acetyl groups reduced its activity (37%).
T8 1005-1203 Sentence denotes Comparing this heparin derivative with 2,3-O-desulphated heparin, the placement of sulphate groups appears important for activity since the two structures have similar nominal linear charge density.
T9 1204-1405 Sentence denotes In addition, unsubstituted uronic acids are nonessential for inhibition since their modification (periodate-oxidation/borohydride-reduction) enhanced rather than reduced heparanase-inhibitory activity.
T10 1406-1675 Sentence denotes The most effective heparanase inhibitors (2,3-O-desulphated heparin, and [periodate-oxidized, borohydride-reduced] heparin) were tested in the chick chorioallantoic membrane (CAM) bioassay for anti-angiogenic activity and found to be at least as efficacious as heparin.
T11 1676-1929 Sentence denotes 2,3-O-desulphated heparin also significantly decreased the tumor growth of a subcutaneous human pancreatic (Ca-Pan-2) adenocarcinoma in nude mice and prolonged the survival times of C57BL/6N mice in a B16-F10 melanoma experimental lung metastasis assay.

GlyCosmos6-Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 26-33 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T2 26-33 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T3 185-192 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T4 185-192 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T5 292-299 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T6 292-299 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T7 577-586 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin's
T8 577-586 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin's
T9 928-937 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin's
T10 928-937 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin's
T11 1020-1027 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T12 1020-1027 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T13 1062-1069 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T14 1062-1069 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T15 1466-1473 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T16 1466-1473 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T17 1521-1528 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T18 1521-1528 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T19 1667-1674 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T20 1667-1674 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin
T21 1694-1701 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T22 1694-1701 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin

GlycoBiology-FMA

Id Subject Object Predicate Lexical cue
_T1 26-33 FMAID:82839 denotes heparin
_T2 26-33 FMAID:167420 denotes heparin
_T3 185-192 FMAID:167420 denotes heparin
_T4 185-192 FMAID:82839 denotes heparin
_T5 292-299 FMAID:167420 denotes heparin
_T6 292-299 FMAID:82839 denotes heparin
_T7 356-363 FMAID:165191 denotes heparan
_T8 356-363 FMAID:67110 denotes heparan
_T9 356-372 FMAID:167405 denotes heparan sulphate
_T10 356-372 FMAID:63023 denotes heparan sulphate
_T11 522-528 FMAID:171168 denotes latter
_T12 522-528 FMAID:30332 denotes latter
_T13 577-584 FMAID:167420 denotes heparin
_T14 577-584 FMAID:82839 denotes heparin
_T15 928-935 FMAID:82839 denotes heparin
_T16 928-935 FMAID:167420 denotes heparin
_T17 1020-1027 FMAID:167420 denotes heparin
_T18 1020-1027 FMAID:82839 denotes heparin
_T19 1062-1069 FMAID:82839 denotes heparin
_T20 1062-1069 FMAID:167420 denotes heparin
_T21 1466-1473 FMAID:167420 denotes heparin
_T22 1466-1473 FMAID:82839 denotes heparin
_T23 1521-1528 FMAID:167420 denotes heparin
_T24 1521-1528 FMAID:82839 denotes heparin
_T25 1535-1541 FMAID:178661 denotes tested
_T26 1581-1584 FMAID:165234 denotes CAM
_T27 1667-1674 FMAID:82839 denotes heparin
_T28 1667-1674 FMAID:167420 denotes heparin
_T29 1694-1701 FMAID:167420 denotes heparin
_T30 1694-1701 FMAID:82839 denotes heparin
_T31 1907-1911 FMAID:7195 denotes lung
_T32 1907-1911 FMAID:169341 denotes lung
_T33 1907-1911 FMAID:93670 denotes lung

uniprot-human

Id Subject Object Predicate Lexical cue
T1 83-93 http://www.uniprot.org/uniprot/Q9Y251 denotes heparanase
T2 219-229 http://www.uniprot.org/uniprot/Q9Y251 denotes heparanase
T3 633-643 http://www.uniprot.org/uniprot/Q9Y251 denotes heparanase
T4 886-896 http://www.uniprot.org/uniprot/Q9Y251 denotes heparanase
T5 1374-1384 http://www.uniprot.org/uniprot/Q9Y251 denotes heparanase
T6 1425-1435 http://www.uniprot.org/uniprot/Q9Y251 denotes heparanase
T7 1581-1584 http://www.uniprot.org/uniprot/Q96HK3 denotes CAM
T8 1881-1884 http://www.uniprot.org/uniprot/P00742 denotes F10
T9 1881-1884 http://www.uniprot.org/uniprot/Q9BQ89 denotes F10

uniprot-mouse

Id Subject Object Predicate Lexical cue
T1 83-93 http://www.uniprot.org/uniprot/Q6YGZ1 denotes heparanase
T2 219-229 http://www.uniprot.org/uniprot/Q6YGZ1 denotes heparanase
T3 633-643 http://www.uniprot.org/uniprot/Q6YGZ1 denotes heparanase
T4 886-896 http://www.uniprot.org/uniprot/Q6YGZ1 denotes heparanase
T5 1374-1384 http://www.uniprot.org/uniprot/Q6YGZ1 denotes heparanase
T6 1425-1435 http://www.uniprot.org/uniprot/Q6YGZ1 denotes heparanase
T7 1812-1816 http://www.uniprot.org/uniprot/Q9CZA6 denotes nude
T8 1881-1884 http://www.uniprot.org/uniprot/O88947 denotes F10

GlycoBiology-NCBITAXON

Id Subject Object Predicate Lexical cue
T1 617-623 http://purl.bioontology.org/ontology/STY/T096 denotes groups
T2 695-701 http://purl.bioontology.org/ontology/STY/T096 denotes groups
T3 949-955 http://purl.bioontology.org/ontology/STY/T096 denotes groups
T4 970-976 http://purl.bioontology.org/ontology/STY/T096 denotes groups
T5 1097-1103 http://purl.bioontology.org/ontology/STY/T096 denotes groups
T6 1787-1790 http://purl.bioontology.org/ontology/NCBITAXON/9596 denotes Pan
T7 1885-1893 http://purl.bioontology.org/ontology/NCBITAXON/45308 denotes melanoma
T8 1885-1893 http://purl.bioontology.org/ontology/NCBITAXON/1369386 denotes melanoma

GO-BP

Id Subject Object Predicate Lexical cue
T1 326-337 http://purl.obolibrary.org/obo/GO_0009056 denotes degradation
T2 463-471 http://purl.obolibrary.org/obo/GO_0009056 denotes degraded
T3 364-372 http://purl.obolibrary.org/obo/GO_0051923 denotes sulphate
T4 591-599 http://purl.obolibrary.org/obo/GO_0051923 denotes sulphate
T5 608-616 http://purl.obolibrary.org/obo/GO_0051923 denotes sulphate
T6 940-948 http://purl.obolibrary.org/obo/GO_0051923 denotes sulphate
T7 1088-1096 http://purl.obolibrary.org/obo/GO_0051923 denotes sulphate
T8 1741-1747 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T9 1784-1786 http://purl.obolibrary.org/obo/GO_0033968 denotes Ca

GO-CC

Id Subject Object Predicate Lexical cue
T1 382-386 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T2 560-563 http://purl.obolibrary.org/obo/GO_0032133 denotes CPC
T3 1571-1579 http://purl.obolibrary.org/obo/GO_0016020 denotes membrane
T4 1787-1790 http://purl.obolibrary.org/obo/GO_0022623 denotes Pan

UBERON-AE

Id Subject Object Predicate Lexical cue
T1 1555-1579 http://purl.obolibrary.org/obo/UBERON_0005335 denotes chorioallantoic membrane
T2 1907-1911 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung

GlycoBiology-MAT

Id Subject Object Predicate Lexical cue
T1 522-528 http://purl.obolibrary.org/obo/MAT_0000488 denotes latter
T2 1907-1911 http://purl.obolibrary.org/obo/MAT_0000135 denotes lung

GlycoBiology-Motifs

Id Subject Object Predicate Lexical cue
T1 26-33 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin
T2 185-192 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin
T3 292-299 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin
T4 1020-1027 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin
T5 1062-1069 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin
T6 1466-1473 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin
T7 1521-1528 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin
T8 1667-1674 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin
T9 1694-1701 http://rdf.glycoinfo.org/glycan/G54161DR denotes heparin

Lectin

Id Subject Object Predicate Lexical cue
Lectin_T1 1784-1786 https://acgg.asia/db/lfdb/LfDB0227 denotes Ca

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1907-1911 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T2 1555-1579 http://purl.obolibrary.org/obo/UBERON_0005335 denotes chorioallantoic membrane

mondo_disease

Id Subject Object Predicate Lexical cue mondo_id
T1 124-129 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T2 376-381 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T3 1735-1740 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T4 1794-1808 Disease denotes adenocarcinoma http://purl.obolibrary.org/obo/MONDO_0004970
T5 1885-1893 Disease denotes melanoma http://purl.obolibrary.org/obo/MONDO_0005105

Anatomy-MAT

Id Subject Object Predicate Lexical cue mat_id
T1 1907-1911 Body_part denotes lung http://purl.obolibrary.org/obo/MAT_0000135

HP-phenotype

Id Subject Object Predicate Lexical cue hp_id
T1 124-129 Phenotype denotes tumor HP:0002664
T2 376-381 Phenotype denotes tumor HP:0002664
T3 1735-1740 Phenotype denotes tumor HP:0002664
T4 1885-1893 Phenotype denotes melanoma HP:0002861

NCBITAXON

Id Subject Object Predicate Lexical cue db_id
T1 1766-1771 OrganismTaxon denotes human 9606
T2 1787-1790 OrganismTaxon denotes Pan 9596
T3 1817-1821 OrganismTaxon denotes mice 10088
T4 1867-1871 OrganismTaxon denotes mice 10088

Anatomy-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 1555-1579 Body_part denotes chorioallantoic membrane http://purl.obolibrary.org/obo/UBERON_0005335
T2 1581-1584 Body_part denotes CAM http://purl.obolibrary.org/obo/UBERON_0005335
T3 1907-1911 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

CL-cell

Id Subject Object Predicate Lexical cue cl_id
T1 376-386 Cell denotes tumor cell http://purl.obolibrary.org/obo/CL:0001063